nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolterodine—CYP2D6—breast cancer	0.117	0.538	CbGaD
Tolterodine—Bromodiphenhydramine—Toremifene—breast cancer	0.102	0.344	CrCrCtD
Tolterodine—CYP3A4—breast cancer	0.1	0.462	CbGaD
Tolterodine—Orphenadrine—Toremifene—breast cancer	0.0801	0.27	CrCrCtD
Tolterodine—Bromodiphenhydramine—Tamoxifen—breast cancer	0.064	0.216	CrCrCtD
Tolterodine—Orphenadrine—Tamoxifen—breast cancer	0.0503	0.17	CrCrCtD
Tolterodine—CYP2C9—Anastrozole—breast cancer	0.0262	0.0857	CbGbCtD
Tolterodine—CYP2C19—Lapatinib—breast cancer	0.0211	0.0688	CbGbCtD
Tolterodine—CYP3A4—Exemestane—breast cancer	0.0201	0.0658	CbGbCtD
Tolterodine—CYP2C9—Idarubicin—breast cancer	0.0199	0.065	CbGbCtD
Tolterodine—CYP2D6—Idarubicin—breast cancer	0.0182	0.0594	CbGbCtD
Tolterodine—CYP3A4—Letrozole—breast cancer	0.0171	0.0559	CbGbCtD
Tolterodine—CYP3A4—Anastrozole—breast cancer	0.0153	0.0498	CbGbCtD
Tolterodine—CYP3A4—Toremifene—breast cancer	0.014	0.0456	CbGbCtD
Tolterodine—CYP3A4—Fulvestrant—breast cancer	0.013	0.0424	CbGbCtD
Tolterodine—CYP3A4—Thiotepa—breast cancer	0.0116	0.0378	CbGbCtD
Tolterodine—CYP2C9—Capecitabine—breast cancer	0.0109	0.0356	CbGbCtD
Tolterodine—CYP3A4—Ixabepilone—breast cancer	0.0106	0.0345	CbGbCtD
Tolterodine—CYP2C19—Tamoxifen—breast cancer	0.0105	0.0344	CbGbCtD
Tolterodine—CYP3A4—Lapatinib—breast cancer	0.0102	0.0333	CbGbCtD
Tolterodine—CYP2D6—Vinorelbine—breast cancer	0.00888	0.029	CbGbCtD
Tolterodine—CYP2C9—Tamoxifen—breast cancer	0.00877	0.0286	CbGbCtD
Tolterodine—CYP2D6—Tamoxifen—breast cancer	0.00802	0.0262	CbGbCtD
Tolterodine—CYP3A4—Raloxifene—breast cancer	0.00772	0.0252	CbGbCtD
Tolterodine—CYP2C9—Paclitaxel—breast cancer	0.00683	0.0223	CbGbCtD
Tolterodine—CYP2C9—Fluorouracil—breast cancer	0.00646	0.0211	CbGbCtD
Tolterodine—CYP3A4—Vinorelbine—breast cancer	0.00565	0.0184	CbGbCtD
Tolterodine—CYP2D6—Vinblastine—breast cancer	0.00547	0.0179	CbGbCtD
Tolterodine—CYP3A4—Tamoxifen—breast cancer	0.0051	0.0166	CbGbCtD
Tolterodine—CYP3A4—Mitoxantrone—breast cancer	0.00497	0.0162	CbGbCtD
Tolterodine—CYP3A4—Paclitaxel—breast cancer	0.00397	0.013	CbGbCtD
Tolterodine—CYP3A4—Irinotecan—breast cancer	0.00392	0.0128	CbGbCtD
Tolterodine—CYP3A4—Vinblastine—breast cancer	0.00348	0.0114	CbGbCtD
Tolterodine—CYP2D6—Doxorubicin—breast cancer	0.00336	0.011	CbGbCtD
Tolterodine—CYP3A4—Docetaxel—breast cancer	0.00287	0.00937	CbGbCtD
Tolterodine—CYP3A4—Doxorubicin—breast cancer	0.00214	0.00698	CbGbCtD
Tolterodine—CHRM3—muscle of abdomen—breast cancer	0.00167	0.292	CbGeAlD
Tolterodine—CHRM5—epithelium—breast cancer	0.000356	0.0621	CbGeAlD
Tolterodine—CHRM5—skin of body—breast cancer	0.000339	0.0591	CbGeAlD
Tolterodine—Fesoterodine—CYP2D6—breast cancer	0.000277	0.148	CrCbGaD
Tolterodine—KCNH2—nipple—breast cancer	0.000262	0.0457	CbGeAlD
Tolterodine—CYP2C9—mammary gland—breast cancer	0.000258	0.0449	CbGeAlD
Tolterodine—Fesoterodine—CYP3A4—breast cancer	0.000238	0.127	CrCbGaD
Tolterodine—Fesoterodine—ABCB1—breast cancer	0.000198	0.106	CrCbGaD
Tolterodine—Orphenadrine—SCN10A—breast cancer	0.000189	0.101	CrCbGaD
Tolterodine—CHRM1—female reproductive system—breast cancer	0.000165	0.0288	CbGeAlD
Tolterodine—CHRM3—adipose tissue—breast cancer	0.000161	0.0281	CbGeAlD
Tolterodine—KCNH2—endometrium—breast cancer	0.000158	0.0276	CbGeAlD
Tolterodine—CHRM2—endocrine gland—breast cancer	0.000154	0.0268	CbGeAlD
Tolterodine—CHRM3—female reproductive system—breast cancer	0.000148	0.0258	CbGeAlD
Tolterodine—KCNH2—uterus—breast cancer	0.000146	0.0254	CbGeAlD
Tolterodine—KCNH2—pituitary gland—breast cancer	0.000143	0.025	CbGeAlD
Tolterodine—CHRM1—endocrine gland—breast cancer	0.00014	0.0244	CbGeAlD
Tolterodine—Labetalol—CYP2D6—breast cancer	0.000138	0.0736	CrCbGaD
Tolterodine—CHRM3—female gonad—breast cancer	0.000135	0.0235	CbGeAlD
Tolterodine—KCNH2—female reproductive system—breast cancer	0.000131	0.0229	CbGeAlD
Tolterodine—KCNH2—adrenal gland—breast cancer	0.000128	0.0223	CbGeAlD
Tolterodine—CHRM3—endocrine gland—breast cancer	0.000125	0.0218	CbGeAlD
Tolterodine—KCNH2—bone marrow—breast cancer	0.000124	0.0216	CbGeAlD
Tolterodine—KCNH2—female gonad—breast cancer	0.000119	0.0208	CbGeAlD
Tolterodine—Oedema—Gemcitabine—breast cancer	0.000119	0.00105	CcSEcCtD
Tolterodine—Anaphylactic shock—Gemcitabine—breast cancer	0.000119	0.00105	CcSEcCtD
Tolterodine—Asthenia—Goserelin—breast cancer	0.000119	0.00105	CcSEcCtD
Tolterodine—Diarrhoea—Tamoxifen—breast cancer	0.000119	0.00105	CcSEcCtD
Tolterodine—Infection—Gemcitabine—breast cancer	0.000119	0.00104	CcSEcCtD
Tolterodine—Confusional state—Fluorouracil—breast cancer	0.000118	0.00104	CcSEcCtD
Tolterodine—Dizziness—Vinblastine—breast cancer	0.000118	0.00104	CcSEcCtD
Tolterodine—Abdominal pain—Vinorelbine—breast cancer	0.000118	0.00103	CcSEcCtD
Tolterodine—Oedema peripheral—Docetaxel—breast cancer	0.000118	0.00103	CcSEcCtD
Tolterodine—Anaphylactic shock—Fluorouracil—breast cancer	0.000117	0.00103	CcSEcCtD
Tolterodine—Oedema—Fluorouracil—breast cancer	0.000117	0.00103	CcSEcCtD
Tolterodine—Feeling abnormal—Thiotepa—breast cancer	0.000117	0.00103	CcSEcCtD
Tolterodine—Infection—Fluorouracil—breast cancer	0.000117	0.00103	CcSEcCtD
Tolterodine—CYP2C19—endocrine gland—breast cancer	0.000116	0.0203	CbGeAlD
Tolterodine—Diarrhoea—Melphalan—breast cancer	0.000116	0.00102	CcSEcCtD
Tolterodine—Gastrointestinal pain—Thiotepa—breast cancer	0.000116	0.00102	CcSEcCtD
Tolterodine—Visual impairment—Docetaxel—breast cancer	0.000115	0.00101	CcSEcCtD
Tolterodine—Dizziness—Tamoxifen—breast cancer	0.000115	0.00101	CcSEcCtD
Tolterodine—Tachycardia—Fluorouracil—breast cancer	0.000115	0.00101	CcSEcCtD
Tolterodine—Oedema peripheral—Capecitabine—breast cancer	0.000114	0.001	CcSEcCtD
Tolterodine—Diarrhoea—Goserelin—breast cancer	0.000114	0.000999	CcSEcCtD
Tolterodine—Abdominal pain—Thiotepa—breast cancer	0.000112	0.000987	CcSEcCtD
Tolterodine—Headache—Vinblastine—breast cancer	0.000112	0.000986	CcSEcCtD
Tolterodine—Angioedema—Paclitaxel—breast cancer	0.000112	0.000985	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Mitoxantrone—breast cancer	0.000112	0.000983	CcSEcCtD
Tolterodine—Visual impairment—Capecitabine—breast cancer	0.000111	0.000979	CcSEcCtD
Tolterodine—Anaphylactoid reaction—Doxorubicin—breast cancer	0.000111	0.000978	CcSEcCtD
Tolterodine—KCNH2—endocrine gland—breast cancer	0.000111	0.0194	CbGeAlD
Tolterodine—Flushing—Docetaxel—breast cancer	0.000111	0.000974	CcSEcCtD
Tolterodine—Vertigo—Paclitaxel—breast cancer	0.00011	0.000968	CcSEcCtD
Tolterodine—Dizziness—Goserelin—breast cancer	0.00011	0.000965	CcSEcCtD
Tolterodine—Hypersensitivity—Vinorelbine—breast cancer	0.00011	0.000963	CcSEcCtD
Tolterodine—Somnolence—Mitoxantrone—breast cancer	0.000109	0.000959	CcSEcCtD
Tolterodine—Somnolence—Irinotecan—breast cancer	0.000109	0.000959	CcSEcCtD
Tolterodine—Headache—Tamoxifen—breast cancer	0.000109	0.000958	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Gemcitabine—breast cancer	0.000109	0.000957	CcSEcCtD
Tolterodine—Palpitations—Paclitaxel—breast cancer	0.000108	0.000952	CcSEcCtD
Tolterodine—Dyspepsia—Irinotecan—breast cancer	0.000108	0.000949	CcSEcCtD
Tolterodine—Dyspepsia—Mitoxantrone—breast cancer	0.000108	0.000949	CcSEcCtD
Tolterodine—Flushing—Capecitabine—breast cancer	0.000107	0.000943	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Fluorouracil—breast cancer	0.000107	0.000941	CcSEcCtD
Tolterodine—CYP2C9—female reproductive system—breast cancer	0.000107	0.0186	CbGeAlD
Tolterodine—Asthenia—Vinorelbine—breast cancer	0.000107	0.000938	CcSEcCtD
Tolterodine—Dry skin—Epirubicin—breast cancer	0.000107	0.000938	CcSEcCtD
Tolterodine—Disopyramide—CYP3A4—breast cancer	0.000106	0.0568	CrCbGaD
Tolterodine—Somnolence—Gemcitabine—breast cancer	0.000106	0.000934	CcSEcCtD
Tolterodine—Fatigue—Irinotecan—breast cancer	0.000106	0.00093	CcSEcCtD
Tolterodine—Fatigue—Mitoxantrone—breast cancer	0.000106	0.00093	CcSEcCtD
Tolterodine—Constipation—Irinotecan—breast cancer	0.000105	0.000922	CcSEcCtD
Tolterodine—Constipation—Mitoxantrone—breast cancer	0.000105	0.000922	CcSEcCtD
Tolterodine—Pain—Mitoxantrone—breast cancer	0.000105	0.000922	CcSEcCtD
Tolterodine—Pain—Irinotecan—breast cancer	0.000105	0.000922	CcSEcCtD
Tolterodine—Hypersensitivity—Thiotepa—breast cancer	0.000105	0.00092	CcSEcCtD
Tolterodine—Somnolence—Fluorouracil—breast cancer	0.000104	0.000918	CcSEcCtD
Tolterodine—Chest pain—Paclitaxel—breast cancer	0.000104	0.000918	CcSEcCtD
Tolterodine—Arthralgia—Paclitaxel—breast cancer	0.000104	0.000918	CcSEcCtD
Tolterodine—Phenprocoumon—CYP3A4—breast cancer	0.000104	0.0557	CrCbGaD
Tolterodine—Headache—Goserelin—breast cancer	0.000104	0.000915	CcSEcCtD
Tolterodine—Anxiety—Paclitaxel—breast cancer	0.000104	0.000914	CcSEcCtD
Tolterodine—Dyspepsia—Fluorouracil—breast cancer	0.000103	0.000909	CcSEcCtD
Tolterodine—Fatigue—Gemcitabine—breast cancer	0.000103	0.000906	CcSEcCtD
Tolterodine—Pain—Gemcitabine—breast cancer	0.000102	0.000898	CcSEcCtD
Tolterodine—Constipation—Gemcitabine—breast cancer	0.000102	0.000898	CcSEcCtD
Tolterodine—Dry mouth—Paclitaxel—breast cancer	0.000102	0.000897	CcSEcCtD
Tolterodine—Asthenia—Thiotepa—breast cancer	0.000102	0.000896	CcSEcCtD
Tolterodine—Diarrhoea—Vinorelbine—breast cancer	0.000102	0.000895	CcSEcCtD
Tolterodine—Feeling abnormal—Irinotecan—breast cancer	0.000101	0.000889	CcSEcCtD
Tolterodine—Feeling abnormal—Mitoxantrone—breast cancer	0.000101	0.000889	CcSEcCtD
Tolterodine—Confusional state—Paclitaxel—breast cancer	0.000101	0.000887	CcSEcCtD
Tolterodine—Dysuria—Methotrexate—breast cancer	0.0001	0.000884	CcSEcCtD
Tolterodine—Pain—Fluorouracil—breast cancer	0.0001	0.000883	CcSEcCtD
Tolterodine—Gastrointestinal pain—Irinotecan—breast cancer	0.0001	0.000882	CcSEcCtD
Tolterodine—Gastrointestinal pain—Mitoxantrone—breast cancer	0.0001	0.000882	CcSEcCtD
Tolterodine—Anaphylactic shock—Paclitaxel—breast cancer	0.0001	0.00088	CcSEcCtD
Tolterodine—Oedema—Paclitaxel—breast cancer	0.0001	0.00088	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Methotrexate—breast cancer	9.98e-05	0.000878	CcSEcCtD
Tolterodine—Infection—Paclitaxel—breast cancer	9.93e-05	0.000874	CcSEcCtD
Tolterodine—Flatulence—Capecitabine—breast cancer	9.91e-05	0.000871	CcSEcCtD
Tolterodine—Dry skin—Doxorubicin—breast cancer	9.86e-05	0.000868	CcSEcCtD
Tolterodine—Feeling abnormal—Gemcitabine—breast cancer	9.84e-05	0.000866	CcSEcCtD
Tolterodine—Dizziness—Vinorelbine—breast cancer	9.83e-05	0.000865	CcSEcCtD
Tolterodine—Tachycardia—Paclitaxel—breast cancer	9.76e-05	0.000858	CcSEcCtD
Tolterodine—Diarrhoea—Thiotepa—breast cancer	9.71e-05	0.000854	CcSEcCtD
Tolterodine—Abdominal pain—Mitoxantrone—breast cancer	9.69e-05	0.000853	CcSEcCtD
Tolterodine—Abdominal pain—Irinotecan—breast cancer	9.69e-05	0.000853	CcSEcCtD
Tolterodine—Feeling abnormal—Fluorouracil—breast cancer	9.68e-05	0.000851	CcSEcCtD
Tolterodine—Bronchitis—Epirubicin—breast cancer	9.67e-05	0.00085	CcSEcCtD
Tolterodine—Dysuria—Epirubicin—breast cancer	9.4e-05	0.000827	CcSEcCtD
Tolterodine—Dizziness—Thiotepa—breast cancer	9.39e-05	0.000826	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Epirubicin—breast cancer	9.34e-05	0.000822	CcSEcCtD
Tolterodine—Headache—Vinorelbine—breast cancer	9.31e-05	0.000819	CcSEcCtD
Tolterodine—Brompheniramine—CYP2D6—breast cancer	9.21e-05	0.0492	CrCbGaD
Tolterodine—Palpitations—Docetaxel—breast cancer	9.18e-05	0.000807	CcSEcCtD
Tolterodine—Weight increased—Epirubicin—breast cancer	9.15e-05	0.000805	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Paclitaxel—breast cancer	9.11e-05	0.000801	CcSEcCtD
Tolterodine—Phenprocoumon—ALB—breast cancer	9.09e-05	0.0486	CrCbGaD
Tolterodine—Chlorphenamine—CYP2D6—breast cancer	9.04e-05	0.0483	CrCbGaD
Tolterodine—Vertigo—Capecitabine—breast cancer	9.03e-05	0.000795	CcSEcCtD
Tolterodine—Hypersensitivity—Mitoxantrone—breast cancer	9.03e-05	0.000795	CcSEcCtD
Tolterodine—Hypersensitivity—Irinotecan—breast cancer	9.03e-05	0.000795	CcSEcCtD
Tolterodine—CYP2C9—endocrine gland—breast cancer	9.03e-05	0.0157	CbGeAlD
Tolterodine—Bronchitis—Doxorubicin—breast cancer	8.95e-05	0.000787	CcSEcCtD
Tolterodine—Headache—Thiotepa—breast cancer	8.89e-05	0.000782	CcSEcCtD
Tolterodine—Somnolence—Paclitaxel—breast cancer	8.89e-05	0.000782	CcSEcCtD
Tolterodine—Palpitations—Capecitabine—breast cancer	8.89e-05	0.000782	CcSEcCtD
Tolterodine—Arthralgia—Docetaxel—breast cancer	8.84e-05	0.000778	CcSEcCtD
Tolterodine—Chest pain—Docetaxel—breast cancer	8.84e-05	0.000778	CcSEcCtD
Tolterodine—Dyspepsia—Paclitaxel—breast cancer	8.8e-05	0.000774	CcSEcCtD
Tolterodine—Asthenia—Mitoxantrone—breast cancer	8.8e-05	0.000774	CcSEcCtD
Tolterodine—Asthenia—Irinotecan—breast cancer	8.8e-05	0.000774	CcSEcCtD
Tolterodine—Urinary tract infection—Epirubicin—breast cancer	8.71e-05	0.000766	CcSEcCtD
Tolterodine—Dysuria—Doxorubicin—breast cancer	8.7e-05	0.000765	CcSEcCtD
Tolterodine—Hypersensitivity—Fluorouracil—breast cancer	8.65e-05	0.000761	CcSEcCtD
Tolterodine—Dry mouth—Docetaxel—breast cancer	8.65e-05	0.000761	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Doxorubicin—breast cancer	8.64e-05	0.00076	CcSEcCtD
Tolterodine—Fatigue—Paclitaxel—breast cancer	8.62e-05	0.000758	CcSEcCtD
Tolterodine—Asthenia—Gemcitabine—breast cancer	8.57e-05	0.000754	CcSEcCtD
Tolterodine—Arthralgia—Capecitabine—breast cancer	8.56e-05	0.000753	CcSEcCtD
Tolterodine—Chest pain—Capecitabine—breast cancer	8.56e-05	0.000753	CcSEcCtD
Tolterodine—Pain—Paclitaxel—breast cancer	8.55e-05	0.000752	CcSEcCtD
Tolterodine—Constipation—Paclitaxel—breast cancer	8.55e-05	0.000752	CcSEcCtD
Tolterodine—Confusional state—Docetaxel—breast cancer	8.55e-05	0.000752	CcSEcCtD
Tolterodine—Anxiety—Capecitabine—breast cancer	8.53e-05	0.00075	CcSEcCtD
Tolterodine—Anaphylactic shock—Docetaxel—breast cancer	8.48e-05	0.000746	CcSEcCtD
Tolterodine—Oedema—Docetaxel—breast cancer	8.48e-05	0.000746	CcSEcCtD
Tolterodine—Weight increased—Doxorubicin—breast cancer	8.46e-05	0.000745	CcSEcCtD
Tolterodine—Infection—Docetaxel—breast cancer	8.42e-05	0.000741	CcSEcCtD
Tolterodine—Sinusitis—Epirubicin—breast cancer	8.41e-05	0.00074	CcSEcCtD
Tolterodine—Diarrhoea—Mitoxantrone—breast cancer	8.39e-05	0.000738	CcSEcCtD
Tolterodine—Diarrhoea—Irinotecan—breast cancer	8.39e-05	0.000738	CcSEcCtD
Tolterodine—Dry mouth—Capecitabine—breast cancer	8.37e-05	0.000736	CcSEcCtD
Tolterodine—Visual impairment—Methotrexate—breast cancer	8.29e-05	0.000729	CcSEcCtD
Tolterodine—Confusional state—Capecitabine—breast cancer	8.27e-05	0.000728	CcSEcCtD
Tolterodine—Tachycardia—Docetaxel—breast cancer	8.27e-05	0.000728	CcSEcCtD
Tolterodine—Feeling abnormal—Paclitaxel—breast cancer	8.24e-05	0.000725	CcSEcCtD
Tolterodine—Oedema—Capecitabine—breast cancer	8.21e-05	0.000722	CcSEcCtD
Tolterodine—Gastrointestinal pain—Paclitaxel—breast cancer	8.18e-05	0.000719	CcSEcCtD
Tolterodine—Diarrhoea—Gemcitabine—breast cancer	8.17e-05	0.000719	CcSEcCtD
Tolterodine—Infection—Capecitabine—breast cancer	8.15e-05	0.000717	CcSEcCtD
Tolterodine—CYP3A4—female reproductive system—breast cancer	8.14e-05	0.0142	CbGeAlD
Tolterodine—Dizziness—Irinotecan—breast cancer	8.11e-05	0.000713	CcSEcCtD
Tolterodine—Urinary tract infection—Doxorubicin—breast cancer	8.06e-05	0.000709	CcSEcCtD
Tolterodine—Diarrhoea—Fluorouracil—breast cancer	8.03e-05	0.000707	CcSEcCtD
Tolterodine—Tachycardia—Capecitabine—breast cancer	8.01e-05	0.000704	CcSEcCtD
Tolterodine—CYP2D6—female reproductive system—breast cancer	8.01e-05	0.0139	CbGeAlD
Tolterodine—Oedema peripheral—Epirubicin—breast cancer	7.93e-05	0.000697	CcSEcCtD
Tolterodine—Abdominal pain—Paclitaxel—breast cancer	7.9e-05	0.000695	CcSEcCtD
Tolterodine—Brompheniramine—CYP3A4—breast cancer	7.9e-05	0.0422	CrCbGaD
Tolterodine—Sinusitis—Doxorubicin—breast cancer	7.78e-05	0.000684	CcSEcCtD
Tolterodine—Dizziness—Fluorouracil—breast cancer	7.76e-05	0.000683	CcSEcCtD
Tolterodine—Visual impairment—Epirubicin—breast cancer	7.75e-05	0.000682	CcSEcCtD
Tolterodine—Chlorphenamine—CYP3A4—breast cancer	7.75e-05	0.0414	CrCbGaD
Tolterodine—Musculoskeletal discomfort—Docetaxel—breast cancer	7.72e-05	0.000679	CcSEcCtD
Tolterodine—Headache—Irinotecan—breast cancer	7.68e-05	0.000676	CcSEcCtD
Tolterodine—Headache—Mitoxantrone—breast cancer	7.68e-05	0.000676	CcSEcCtD
Tolterodine—KCNH2—lymph node—breast cancer	7.68e-05	0.0134	CbGeAlD
Tolterodine—Atomoxetine—CYP2D6—breast cancer	7.59e-05	0.0406	CrCbGaD
Tolterodine—Somnolence—Docetaxel—breast cancer	7.53e-05	0.000663	CcSEcCtD
Tolterodine—Headache—Gemcitabine—breast cancer	7.48e-05	0.000658	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Capecitabine—breast cancer	7.48e-05	0.000658	CcSEcCtD
Tolterodine—Flushing—Epirubicin—breast cancer	7.47e-05	0.000657	CcSEcCtD
Tolterodine—Dyspepsia—Docetaxel—breast cancer	7.46e-05	0.000656	CcSEcCtD
Tolterodine—Hypersensitivity—Paclitaxel—breast cancer	7.37e-05	0.000648	CcSEcCtD
Tolterodine—Headache—Fluorouracil—breast cancer	7.36e-05	0.000647	CcSEcCtD
Tolterodine—Oedema peripheral—Doxorubicin—breast cancer	7.33e-05	0.000645	CcSEcCtD
Tolterodine—Fatigue—Docetaxel—breast cancer	7.31e-05	0.000643	CcSEcCtD
Tolterodine—CYP2D6—female gonad—breast cancer	7.29e-05	0.0127	CbGeAlD
Tolterodine—Constipation—Docetaxel—breast cancer	7.25e-05	0.000638	CcSEcCtD
Tolterodine—Pain—Docetaxel—breast cancer	7.25e-05	0.000638	CcSEcCtD
Tolterodine—Dyspepsia—Capecitabine—breast cancer	7.22e-05	0.000635	CcSEcCtD
Tolterodine—Visual impairment—Doxorubicin—breast cancer	7.17e-05	0.000631	CcSEcCtD
Tolterodine—Asthenia—Paclitaxel—breast cancer	7.17e-05	0.000631	CcSEcCtD
Tolterodine—Fatigue—Capecitabine—breast cancer	7.07e-05	0.000622	CcSEcCtD
Tolterodine—Pain—Capecitabine—breast cancer	7.02e-05	0.000617	CcSEcCtD
Tolterodine—Constipation—Capecitabine—breast cancer	7.02e-05	0.000617	CcSEcCtD
Tolterodine—Feeling abnormal—Docetaxel—breast cancer	6.98e-05	0.000614	CcSEcCtD
Tolterodine—Gastrointestinal pain—Docetaxel—breast cancer	6.93e-05	0.00061	CcSEcCtD
Tolterodine—Flushing—Doxorubicin—breast cancer	6.91e-05	0.000608	CcSEcCtD
Tolterodine—Flatulence—Epirubicin—breast cancer	6.9e-05	0.000607	CcSEcCtD
Tolterodine—CYP3A4—endocrine gland—breast cancer	6.89e-05	0.012	CbGeAlD
Tolterodine—Diarrhoea—Paclitaxel—breast cancer	6.84e-05	0.000602	CcSEcCtD
Tolterodine—CYP2D6—endocrine gland—breast cancer	6.78e-05	0.0118	CbGeAlD
Tolterodine—Feeling abnormal—Capecitabine—breast cancer	6.76e-05	0.000595	CcSEcCtD
Tolterodine—Vertigo—Methotrexate—breast cancer	6.72e-05	0.000592	CcSEcCtD
Tolterodine—Gastrointestinal pain—Capecitabine—breast cancer	6.71e-05	0.00059	CcSEcCtD
Tolterodine—Abdominal pain—Docetaxel—breast cancer	6.7e-05	0.000589	CcSEcCtD
Tolterodine—Dizziness—Paclitaxel—breast cancer	6.61e-05	0.000582	CcSEcCtD
Tolterodine—Atomoxetine—CYP3A4—breast cancer	6.51e-05	0.0348	CrCbGaD
Tolterodine—Abdominal pain—Capecitabine—breast cancer	6.49e-05	0.000571	CcSEcCtD
Tolterodine—Flatulence—Doxorubicin—breast cancer	6.39e-05	0.000562	CcSEcCtD
Tolterodine—Arthralgia—Methotrexate—breast cancer	6.37e-05	0.000561	CcSEcCtD
Tolterodine—Chest pain—Methotrexate—breast cancer	6.37e-05	0.000561	CcSEcCtD
Tolterodine—Vertigo—Epirubicin—breast cancer	6.29e-05	0.000554	CcSEcCtD
Tolterodine—Headache—Paclitaxel—breast cancer	6.26e-05	0.000551	CcSEcCtD
Tolterodine—Hypersensitivity—Docetaxel—breast cancer	6.24e-05	0.000549	CcSEcCtD
Tolterodine—Palpitations—Epirubicin—breast cancer	6.19e-05	0.000544	CcSEcCtD
Tolterodine—Confusional state—Methotrexate—breast cancer	6.16e-05	0.000542	CcSEcCtD
Tolterodine—Anaphylactic shock—Methotrexate—breast cancer	6.11e-05	0.000537	CcSEcCtD
Tolterodine—Asthenia—Docetaxel—breast cancer	6.08e-05	0.000535	CcSEcCtD
Tolterodine—Infection—Methotrexate—breast cancer	6.07e-05	0.000534	CcSEcCtD
Tolterodine—Hypersensitivity—Capecitabine—breast cancer	6.05e-05	0.000532	CcSEcCtD
Tolterodine—Arthralgia—Epirubicin—breast cancer	5.96e-05	0.000525	CcSEcCtD
Tolterodine—Chest pain—Epirubicin—breast cancer	5.96e-05	0.000525	CcSEcCtD
Tolterodine—Anxiety—Epirubicin—breast cancer	5.94e-05	0.000523	CcSEcCtD
Tolterodine—Asthenia—Capecitabine—breast cancer	5.89e-05	0.000518	CcSEcCtD
Tolterodine—Dry mouth—Epirubicin—breast cancer	5.83e-05	0.000513	CcSEcCtD
Tolterodine—Vertigo—Doxorubicin—breast cancer	5.82e-05	0.000512	CcSEcCtD
Tolterodine—Diarrhoea—Docetaxel—breast cancer	5.8e-05	0.00051	CcSEcCtD
Tolterodine—Confusional state—Epirubicin—breast cancer	5.76e-05	0.000507	CcSEcCtD
Tolterodine—Palpitations—Doxorubicin—breast cancer	5.73e-05	0.000504	CcSEcCtD
Tolterodine—Oedema—Epirubicin—breast cancer	5.72e-05	0.000503	CcSEcCtD
Tolterodine—Anaphylactic shock—Epirubicin—breast cancer	5.72e-05	0.000503	CcSEcCtD
Tolterodine—Infection—Epirubicin—breast cancer	5.68e-05	0.0005	CcSEcCtD
Tolterodine—Diarrhoea—Capecitabine—breast cancer	5.61e-05	0.000494	CcSEcCtD
Tolterodine—Dizziness—Docetaxel—breast cancer	5.6e-05	0.000493	CcSEcCtD
Tolterodine—Tachycardia—Epirubicin—breast cancer	5.58e-05	0.000491	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Methotrexate—breast cancer	5.57e-05	0.00049	CcSEcCtD
Tolterodine—Chest pain—Doxorubicin—breast cancer	5.52e-05	0.000485	CcSEcCtD
Tolterodine—Arthralgia—Doxorubicin—breast cancer	5.52e-05	0.000485	CcSEcCtD
Tolterodine—Anxiety—Doxorubicin—breast cancer	5.5e-05	0.000484	CcSEcCtD
Tolterodine—Somnolence—Methotrexate—breast cancer	5.43e-05	0.000478	CcSEcCtD
Tolterodine—Dizziness—Capecitabine—breast cancer	5.43e-05	0.000477	CcSEcCtD
Tolterodine—Dry mouth—Doxorubicin—breast cancer	5.4e-05	0.000475	CcSEcCtD
Tolterodine—Dyspepsia—Methotrexate—breast cancer	5.38e-05	0.000473	CcSEcCtD
Tolterodine—Confusional state—Doxorubicin—breast cancer	5.33e-05	0.000469	CcSEcCtD
Tolterodine—Headache—Docetaxel—breast cancer	5.31e-05	0.000467	CcSEcCtD
Tolterodine—Anaphylactic shock—Doxorubicin—breast cancer	5.29e-05	0.000465	CcSEcCtD
Tolterodine—Oedema—Doxorubicin—breast cancer	5.29e-05	0.000465	CcSEcCtD
Tolterodine—Fatigue—Methotrexate—breast cancer	5.27e-05	0.000463	CcSEcCtD
Tolterodine—Infection—Doxorubicin—breast cancer	5.25e-05	0.000462	CcSEcCtD
Tolterodine—Pain—Methotrexate—breast cancer	5.22e-05	0.000459	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Epirubicin—breast cancer	5.21e-05	0.000458	CcSEcCtD
Tolterodine—Tachycardia—Doxorubicin—breast cancer	5.16e-05	0.000454	CcSEcCtD
Tolterodine—Headache—Capecitabine—breast cancer	5.14e-05	0.000452	CcSEcCtD
Tolterodine—Somnolence—Epirubicin—breast cancer	5.08e-05	0.000447	CcSEcCtD
Tolterodine—Feeling abnormal—Methotrexate—breast cancer	5.03e-05	0.000443	CcSEcCtD
Tolterodine—Dyspepsia—Epirubicin—breast cancer	5.03e-05	0.000443	CcSEcCtD
Tolterodine—Gastrointestinal pain—Methotrexate—breast cancer	5e-05	0.000439	CcSEcCtD
Tolterodine—Orphenadrine—CYP3A4—breast cancer	4.98e-05	0.0266	CrCbGaD
Tolterodine—Fatigue—Epirubicin—breast cancer	4.93e-05	0.000434	CcSEcCtD
Tolterodine—Constipation—Epirubicin—breast cancer	4.89e-05	0.00043	CcSEcCtD
Tolterodine—Pain—Epirubicin—breast cancer	4.89e-05	0.00043	CcSEcCtD
Tolterodine—Abdominal pain—Methotrexate—breast cancer	4.83e-05	0.000425	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Doxorubicin—breast cancer	4.82e-05	0.000424	CcSEcCtD
Tolterodine—Feeling abnormal—Epirubicin—breast cancer	4.71e-05	0.000414	CcSEcCtD
Tolterodine—Somnolence—Doxorubicin—breast cancer	4.7e-05	0.000414	CcSEcCtD
Tolterodine—Gastrointestinal pain—Epirubicin—breast cancer	4.67e-05	0.000411	CcSEcCtD
Tolterodine—Dyspepsia—Doxorubicin—breast cancer	4.66e-05	0.00041	CcSEcCtD
Tolterodine—Fatigue—Doxorubicin—breast cancer	4.56e-05	0.000401	CcSEcCtD
Tolterodine—Constipation—Doxorubicin—breast cancer	4.52e-05	0.000398	CcSEcCtD
Tolterodine—Pain—Doxorubicin—breast cancer	4.52e-05	0.000398	CcSEcCtD
Tolterodine—Abdominal pain—Epirubicin—breast cancer	4.52e-05	0.000398	CcSEcCtD
Tolterodine—Hypersensitivity—Methotrexate—breast cancer	4.5e-05	0.000396	CcSEcCtD
Tolterodine—Asthenia—Methotrexate—breast cancer	4.38e-05	0.000386	CcSEcCtD
Tolterodine—Feeling abnormal—Doxorubicin—breast cancer	4.36e-05	0.000383	CcSEcCtD
Tolterodine—Gastrointestinal pain—Doxorubicin—breast cancer	4.33e-05	0.00038	CcSEcCtD
Tolterodine—Hypersensitivity—Epirubicin—breast cancer	4.21e-05	0.00037	CcSEcCtD
Tolterodine—Abdominal pain—Doxorubicin—breast cancer	4.18e-05	0.000368	CcSEcCtD
Tolterodine—Diarrhoea—Methotrexate—breast cancer	4.18e-05	0.000368	CcSEcCtD
Tolterodine—Asthenia—Epirubicin—breast cancer	4.1e-05	0.000361	CcSEcCtD
Tolterodine—Dizziness—Methotrexate—breast cancer	4.04e-05	0.000355	CcSEcCtD
Tolterodine—Diarrhoea—Epirubicin—breast cancer	3.91e-05	0.000344	CcSEcCtD
Tolterodine—Hypersensitivity—Doxorubicin—breast cancer	3.9e-05	0.000343	CcSEcCtD
Tolterodine—Headache—Methotrexate—breast cancer	3.83e-05	0.000337	CcSEcCtD
Tolterodine—Asthenia—Doxorubicin—breast cancer	3.79e-05	0.000334	CcSEcCtD
Tolterodine—Dizziness—Epirubicin—breast cancer	3.78e-05	0.000333	CcSEcCtD
Tolterodine—Diarrhoea—Doxorubicin—breast cancer	3.62e-05	0.000318	CcSEcCtD
Tolterodine—Headache—Epirubicin—breast cancer	3.58e-05	0.000315	CcSEcCtD
Tolterodine—Dizziness—Doxorubicin—breast cancer	3.5e-05	0.000308	CcSEcCtD
Tolterodine—Headache—Doxorubicin—breast cancer	3.31e-05	0.000291	CcSEcCtD
Tolterodine—CYP2C9—Metabolism—PLA2G4A—breast cancer	2.7e-06	4.56e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—GSTM1—breast cancer	2.7e-06	4.56e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—MMP9—breast cancer	2.68e-06	4.53e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—MAPK3—breast cancer	2.68e-06	4.53e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—CDKN1A—breast cancer	2.67e-06	4.52e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—PTEN—breast cancer	2.67e-06	4.51e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—BRAF—breast cancer	2.67e-06	4.5e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—BRAF—breast cancer	2.66e-06	4.49e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CYP17A1—breast cancer	2.65e-06	4.47e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—BRAF—breast cancer	2.63e-06	4.45e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PTGS1—breast cancer	2.62e-06	4.42e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—ENO1—breast cancer	2.62e-06	4.42e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—MTHFR—breast cancer	2.62e-06	4.42e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—MAPK8—breast cancer	2.61e-06	4.41e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—GPX1—breast cancer	2.61e-06	4.41e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—AKT1—breast cancer	2.6e-06	4.4e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—IGF1—breast cancer	2.6e-06	4.39e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—AKT2—breast cancer	2.59e-06	4.38e-05	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—PIK3CB—breast cancer	2.59e-06	4.38e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—IGF1—breast cancer	2.59e-06	4.37e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—AKT2—breast cancer	2.59e-06	4.37e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—GPX1—breast cancer	2.58e-06	4.37e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—EGFR—breast cancer	2.58e-06	4.37e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—SRC—breast cancer	2.58e-06	4.36e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—CYP1A1—breast cancer	2.58e-06	4.36e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—EGFR—breast cancer	2.58e-06	4.35e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CYP2D6—breast cancer	2.57e-06	4.34e-05	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—PTGS2—breast cancer	2.57e-06	4.34e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—IGF1—breast cancer	2.56e-06	4.33e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—AKT2—breast cancer	2.56e-06	4.33e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—ERCC2—breast cancer	2.56e-06	4.33e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—CYP1A1—breast cancer	2.56e-06	4.32e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—EGFR—breast cancer	2.55e-06	4.31e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—ERCC2—breast cancer	2.54e-06	4.29e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—NCOA2—breast cancer	2.52e-06	4.26e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—VEGFA—breast cancer	2.52e-06	4.25e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—PIK3CD—breast cancer	2.49e-06	4.21e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—STAT3—breast cancer	2.49e-06	4.21e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—PIK3CD—breast cancer	2.49e-06	4.2e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—SRC—breast cancer	2.47e-06	4.18e-05	CbGpPWpGaD
Tolterodine—CHRM1—GPCR downstream signaling—PIK3CA—breast cancer	2.47e-06	4.17e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—SERPINE1—breast cancer	2.47e-06	4.17e-05	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—PIK3CA—breast cancer	2.46e-06	4.16e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—PIK3CD—breast cancer	2.46e-06	4.16e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—SERPINE1—breast cancer	2.46e-06	4.15e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—FASN—breast cancer	2.44e-06	4.13e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—KRAS—breast cancer	2.44e-06	4.12e-05	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—PIK3CA—breast cancer	2.44e-06	4.12e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—BCHE—breast cancer	2.43e-06	4.11e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—SERPINE1—breast cancer	2.43e-06	4.11e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—KRAS—breast cancer	2.43e-06	4.11e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—CAV1—breast cancer	2.41e-06	4.08e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—KRAS—breast cancer	2.41e-06	4.07e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—VEGFA—breast cancer	2.41e-06	4.07e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—MTHFR—breast cancer	2.41e-06	4.07e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—SLC5A5—breast cancer	2.4e-06	4.06e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—MTHFR—breast cancer	2.39e-06	4.03e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—STAT3—breast cancer	2.39e-06	4.03e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—MAPK3—breast cancer	2.38e-06	4.02e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—NOS3—breast cancer	2.35e-06	3.98e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—NOS3—breast cancer	2.35e-06	3.97e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—NOS3—breast cancer	2.32e-06	3.93e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—NQO1—breast cancer	2.32e-06	3.92e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—SLC2A1—breast cancer	2.32e-06	3.92e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—MYC—breast cancer	2.31e-06	3.91e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—TGFB1—breast cancer	2.31e-06	3.9e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	2.31e-06	3.9e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—MAPK3—breast cancer	2.28e-06	3.85e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—EGFR—breast cancer	2.26e-06	3.83e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—PIK3CA—breast cancer	2.24e-06	3.79e-05	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—PTEN—breast cancer	2.24e-06	3.78e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—PIK3CA—breast cancer	2.24e-06	3.78e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—MDM2—breast cancer	2.23e-06	3.77e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CYP1B1—breast cancer	2.23e-06	3.76e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—MDM2—breast cancer	2.23e-06	3.76e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—RAF1—breast cancer	2.23e-06	3.76e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—CAV1—breast cancer	2.22e-06	3.75e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—RAF1—breast cancer	2.22e-06	3.75e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—MYC—breast cancer	2.22e-06	3.75e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—RELA—breast cancer	2.22e-06	3.74e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—PIK3CA—breast cancer	2.21e-06	3.74e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—TGFB1—breast cancer	2.21e-06	3.74e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—RELA—breast cancer	2.21e-06	3.73e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—MDM2—breast cancer	2.2e-06	3.73e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—ERBB2—breast cancer	2.2e-06	3.72e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—CAV1—breast cancer	2.2e-06	3.72e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PIK3CG—breast cancer	2.2e-06	3.71e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—RAF1—breast cancer	2.2e-06	3.71e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—ERBB2—breast cancer	2.2e-06	3.71e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—RELA—breast cancer	2.19e-06	3.7e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—HSP90AA1—breast cancer	2.18e-06	3.69e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—ERBB2—breast cancer	2.17e-06	3.67e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—PIK3CB—breast cancer	2.17e-06	3.67e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—MTOR—breast cancer	2.17e-06	3.67e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—EGFR—breast cancer	2.17e-06	3.66e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—PIK3CB—breast cancer	2.17e-06	3.66e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—MTOR—breast cancer	2.17e-06	3.66e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—MTOR—breast cancer	2.15e-06	3.62e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—PIK3CB—breast cancer	2.15e-06	3.62e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—KRAS—breast cancer	2.14e-06	3.61e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—NCOA1—breast cancer	2.12e-06	3.59e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	2.1e-06	3.55e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CYP19A1—breast cancer	2.09e-06	3.54e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—STK11—breast cancer	2.09e-06	3.54e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CXCL8—breast cancer	2.09e-06	3.53e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CXCL8—breast cancer	2.08e-06	3.52e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—HRAS—breast cancer	2.07e-06	3.51e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—HRAS—breast cancer	2.07e-06	3.49e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CXCL8—breast cancer	2.06e-06	3.48e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—HRAS—breast cancer	2.05e-06	3.46e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—KRAS—breast cancer	2.05e-06	3.46e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CDKN1B—breast cancer	2.04e-06	3.45e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CDKN1B—breast cancer	2.03e-06	3.44e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PIK3CG—breast cancer	2.02e-06	3.42e-05	CbGpPWpGaD
Tolterodine—CHRM1—GPCR downstream signaling—AKT1—breast cancer	2.02e-06	3.41e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CDKN1B—breast cancer	2.01e-06	3.4e-05	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—AKT1—breast cancer	2.01e-06	3.4e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PIK3CG—breast cancer	2e-06	3.39e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CASP3—breast cancer	2e-06	3.38e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—IL2—breast cancer	2e-06	3.37e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CASP3—breast cancer	1.99e-06	3.37e-05	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—AKT1—breast cancer	1.99e-06	3.37e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—IL2—breast cancer	1.99e-06	3.36e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—IL6—breast cancer	1.99e-06	3.36e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—IL6—breast cancer	1.98e-06	3.34e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CASP3—breast cancer	1.97e-06	3.33e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—IL2—breast cancer	1.97e-06	3.33e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—PIK3CA—breast cancer	1.96e-06	3.32e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—IL6—breast cancer	1.96e-06	3.31e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—COMT—breast cancer	1.95e-06	3.29e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CCND1—breast cancer	1.95e-06	3.29e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—JUN—breast cancer	1.94e-06	3.28e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CCND1—breast cancer	1.94e-06	3.28e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—GSTP1—breast cancer	1.94e-06	3.27e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—JUN—breast cancer	1.94e-06	3.27e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PIK3CD—breast cancer	1.93e-06	3.26e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CTNNB1—breast cancer	1.93e-06	3.26e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CCND1—breast cancer	1.92e-06	3.25e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CTNNB1—breast cancer	1.92e-06	3.25e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—JUN—breast cancer	1.92e-06	3.24e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—HMOX1—breast cancer	1.91e-06	3.23e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—ALB—breast cancer	1.91e-06	3.22e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—ITPR1—breast cancer	1.91e-06	3.22e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CTNNB1—breast cancer	1.9e-06	3.21e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—TP53—breast cancer	1.9e-06	3.21e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—MMP9—breast cancer	1.89e-06	3.19e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—MMP9—breast cancer	1.88e-06	3.18e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CDKN1A—breast cancer	1.88e-06	3.18e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—PIK3CA—breast cancer	1.88e-06	3.18e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—PTEN—breast cancer	1.88e-06	3.17e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CDKN1A—breast cancer	1.88e-06	3.17e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—PTEN—breast cancer	1.87e-06	3.16e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—MMP9—breast cancer	1.86e-06	3.15e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CDKN1A—breast cancer	1.86e-06	3.14e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—PTEN—breast cancer	1.85e-06	3.13e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—MAPK8—breast cancer	1.84e-06	3.1e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—ABCB1—breast cancer	1.83e-06	3.1e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—AKT1—breast cancer	1.83e-06	3.1e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—MAPK8—breast cancer	1.83e-06	3.09e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—AKT1—breast cancer	1.83e-06	3.09e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—NOS3—breast cancer	1.82e-06	3.08e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—TP53—breast cancer	1.82e-06	3.08e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—HRAS—breast cancer	1.82e-06	3.07e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—MAPK8—breast cancer	1.81e-06	3.06e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—AKT1—breast cancer	1.81e-06	3.06e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—TYMS—breast cancer	1.8e-06	3.04e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—GSTM1—breast cancer	1.78e-06	3.01e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—NCOR1—breast cancer	1.78e-06	3.01e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PLA2G4A—breast cancer	1.78e-06	3.01e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PIK3CD—breast cancer	1.78e-06	3e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PIK3CD—breast cancer	1.76e-06	2.98e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—ALB—breast cancer	1.75e-06	2.96e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—SRC—breast cancer	1.74e-06	2.94e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—HRAS—breast cancer	1.74e-06	2.94e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—IL6—breast cancer	1.74e-06	2.94e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—ALB—breast cancer	1.74e-06	2.94e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—SRC—breast cancer	1.74e-06	2.93e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—SRC—breast cancer	1.72e-06	2.9e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—GPX1—breast cancer	1.7e-06	2.88e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—VEGFA—breast cancer	1.7e-06	2.87e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—VEGFA—breast cancer	1.69e-06	2.86e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CYP1A1—breast cancer	1.69e-06	2.85e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PIK3CB—breast cancer	1.68e-06	2.85e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—STAT3—breast cancer	1.68e-06	2.84e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—NOS3—breast cancer	1.68e-06	2.84e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—VEGFA—breast cancer	1.67e-06	2.83e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—STAT3—breast cancer	1.67e-06	2.83e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—ERCC2—breast cancer	1.67e-06	2.83e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PTGS2—breast cancer	1.67e-06	2.82e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—IL6—breast cancer	1.67e-06	2.82e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—NOS3—breast cancer	1.66e-06	2.81e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—STAT3—breast cancer	1.66e-06	2.8e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—AKT1—breast cancer	1.6e-06	2.71e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—MAPK3—breast cancer	1.6e-06	2.71e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—MAPK3—breast cancer	1.6e-06	2.7e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—MAPK3—breast cancer	1.58e-06	2.68e-05	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—PIK3CA—breast cancer	1.58e-06	2.67e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—MTHFR—breast cancer	1.57e-06	2.66e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—MYC—breast cancer	1.56e-06	2.64e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—TGFB1—breast cancer	1.56e-06	2.63e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—MYC—breast cancer	1.56e-06	2.63e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—TGFB1—breast cancer	1.55e-06	2.62e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PIK3CB—breast cancer	1.55e-06	2.62e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—MYC—breast cancer	1.54e-06	2.6e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—AKT1—breast cancer	1.54e-06	2.6e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—TGFB1—breast cancer	1.54e-06	2.6e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PIK3CB—breast cancer	1.54e-06	2.59e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PTGS2—breast cancer	1.53e-06	2.59e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—EGFR—breast cancer	1.53e-06	2.58e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PTGS2—breast cancer	1.52e-06	2.57e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—EGFR—breast cancer	1.52e-06	2.57e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—EGFR—breast cancer	1.51e-06	2.55e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PTEN—breast cancer	1.46e-06	2.46e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CAV1—breast cancer	1.45e-06	2.45e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—KRAS—breast cancer	1.44e-06	2.44e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—KRAS—breast cancer	1.44e-06	2.43e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—KRAS—breast cancer	1.42e-06	2.41e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PTEN—breast cancer	1.34e-06	2.26e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PTEN—breast cancer	1.33e-06	2.24e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—PIK3CA—breast cancer	1.32e-06	2.24e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PIK3CG—breast cancer	1.32e-06	2.23e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—PIK3CA—breast cancer	1.32e-06	2.23e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—PIK3CA—breast cancer	1.31e-06	2.21e-05	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—AKT1—breast cancer	1.29e-06	2.18e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—TP53—breast cancer	1.28e-06	2.17e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—TP53—breast cancer	1.28e-06	2.16e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—TP53—breast cancer	1.27e-06	2.14e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—HRAS—breast cancer	1.23e-06	2.07e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—HRAS—breast cancer	1.22e-06	2.06e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—HRAS—breast cancer	1.21e-06	2.04e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—IL6—breast cancer	1.17e-06	1.98e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—IL6—breast cancer	1.17e-06	1.98e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PIK3CD—breast cancer	1.16e-06	1.96e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—IL6—breast cancer	1.16e-06	1.96e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—ALB—breast cancer	1.15e-06	1.94e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—NOS3—breast cancer	1.1e-06	1.85e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—AKT1—breast cancer	1.08e-06	1.83e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—AKT1—breast cancer	1.08e-06	1.82e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—AKT1—breast cancer	1.07e-06	1.81e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PIK3CA—breast cancer	1.03e-06	1.73e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PIK3CB—breast cancer	1.01e-06	1.71e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PTGS2—breast cancer	1e-06	1.7e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PIK3CA—breast cancer	9.44e-07	1.6e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PIK3CA—breast cancer	9.36e-07	1.58e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PTEN—breast cancer	8.75e-07	1.48e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—AKT1—breast cancer	8.39e-07	1.42e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—AKT1—breast cancer	7.71e-07	1.3e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—AKT1—breast cancer	7.65e-07	1.29e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PIK3CA—breast cancer	6.17e-07	1.04e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—AKT1—breast cancer	5.04e-07	8.52e-06	CbGpPWpGaD
